- Autor
-
Pracoviště
BioTechMed Graz 8010 Graz Austria 1 Department for Biomedical Research Me... 1 Department of Biology Faculty of Medi... 1 Department of Medical and Surgical Sc... 1 Division of Hematology Department of ... 1 Division of Molecular Biology and Bio... 1 Division of Oncology Department of In... 1 Research Unit for Non Coding RNA and ... 1 Translational Oncology 2 Med Clinics ... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
-
Pracoviště
BioTechMed Graz 8010 Graz Austria 1 Department for Biomedical Research Me... 1 Department of Biology Faculty of Medi... 1 Department of Medical and Surgical Sc... 1 Division of Hematology Department of ... 1 Division of Molecular Biology and Bio... 1 Division of Oncology Department of In... 1 Research Unit for Non Coding RNA and ... 1 Translational Oncology 2 Med Clinics ... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Jonas, Katharina
- Prinz, Felix
- Ferracin, Manuela
- Krajina, Katarina
- Deutsch, Alexander
- Madl, Tobias
- Rinner, Beate
- Slaby, Ondrej
- Klec, Christiane
-
Pichler, Martin
Autor Pichler, Martin ORCID Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria Research Unit for Non-Coding RNA and Genome Editing, Medical University of Graz, 8010 Graz, Austria Translational Oncology, II. Med Clinics Hematology and Oncology, 86156 Augsburg, Germany
NLK
Directory of Open Access Journals
od 2015
PubMed Central
od 2015
Europe PubMed Central
od 2015
ProQuest Central
od 2015-06-01
Open Access Digital Library
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2015
PubMed
38250802
DOI
10.3390/ncrna10010002
Knihovny.cz E-zdroje
MicroRNAs (miRNAs) are crucial post-transcriptional regulators of gene expression, and their deregulation contributes to many aspects of cancer development and progression. Thus, miRNAs provide insight into oncogenic mechanisms and represent promising targets for new therapeutic approaches. A type of cancer that is still in urgent need of improved treatment options is triple negative breast cancer (TNBC). Therefore, we aimed to characterize a novel miRNA with a potential role in TNBC. Based on a previous study, we selected miR-4646-5p, a miRNA with a still unknown function in breast cancer. We discovered that higher expression of miR-4646-5p in TNBC patients is associated with better survival. In vitro assays showed that miR-4646-5p overexpression reduces growth, proliferation, and migration of TNBC cell lines, whereas inhibition had the opposite effect. Furthermore, we found that miR-4646-5p inhibits the tube formation ability of endothelial cells, which may indicate anti-angiogenic properties. By whole transcriptome analysis, we not only observed that miR-4646-5p downregulates many oncogenic factors, like tumor-promoting cytokines and migration- and invasion-related genes, but were also able to identify a direct target, the GRAM domain-containing protein 1B (GRAMD1B). GRAMD1B is involved in cellular cholesterol transport and its knockdown phenocopied the growth-reducing effects of miR-4646-5p. We thus conclude that GRAMD1B may partly contribute to the diverse tumor-suppressive effects of miR-4646-5p in TNBC.
- Publikační typ
- časopisecké články MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.